Endometrial cancer trials in China
86 trials · From ClinicalTrials.gov, checked 10 Nov 2026. Ask the study team whether a trial fits you.
Phase 1/2RecruitingTrial-stage medicine
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Guangdong, Hangzhou, Henan, Hubei, Nanchang, Shanghai, Shanxi, Shengyang, Tianjin
- Age
- 18 years and over
- People
- 952 worldwide
- Run by
- Genmab
See details and how to joinNCT05579366Registry updated 2026-11-04
Phase 2RecruitingTrial-stage medicine
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Beijing, Changsha, Hangzhou, Shanghai
- Age
- 18 years and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819EU 2024-517419-62-00Registry updated 2026-11-04
Phase 3RecruitingTrial-stage medicine
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Pfizer
See details and how to joinNCT07578649EU 2026-525584-40-00Registry updated 2026-10-30
Phase 1RecruitingTrial-stage medicine
A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors
- Where
- Shanghai
- Age
- 18 years and over
- People
- 128
- Run by
- TJ Biopharma Co., Ltd.
See details and how to joinNCT07715747Registry updated 2026-10-30
Phase 3RecruitingTrial-stage medicine
HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer
- Where
- Guangzhou, Shenyang
- Age
- 18 years and over
- People
- 333
- Run by
- Shanghai Huaota Biopharmaceutical Co., Ltd.
See details and how to joinNCT07902999Registry updated 2026-10-29
Phase 3RecruitingTrial-stage medicine
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
- Where
- Beijing, Changchun, Chengdu, Hangzhou, Jinan, Linyi, Nanchang, Nanning, Shanghai, Tianjin, Wenzhou, Wuhan, Yantai
- Age
- 18 years and over
- People
- 710 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT07022483EU 2024-519444-33-00Registry updated 2026-10-27
Phase 2RecruitingTrial-stage medicine
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Chengdu, Guangzhou
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478EU 2023-507641-29-00Registry updated 2026-10-26
Phase 1RecruitingTrial-stage medicine
A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 96
- Run by
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT06531486Registry updated 2026-10-26
No phaseRecruitingResearch participation
Feasibility of the "One-Finger Technique" for Identifying the Upper Left Ureter During Para-Aortic Lymphadenectomy
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 40
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07895212Registry updated 2026-10-26
No phaseRecruitingResearch participation
Liquid Biopsy-Based Early Screening for Endometrial Cancer in Regional Chinese Populations
- Where
- Guiyang
- Age
- Up to 18 years
- People
- 512
- Run by
- Guizhou Provincial People's Hospital
See details and how to joinNCT07892755Registry updated 2026-10-23
Phase 2Not yet recruitingTrial-stage medicine
Canagliflozin Plus Progestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial Cancer
- Where
- Tianjin
- Age
- 18 years to 45 years
- People
- 102
- Run by
- Wang Yingmei
See details and how to joinNCT07890064Registry updated 2026-10-22
Phase 3RecruitingTrial-stage medicine
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- Where
- Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Lanzhou, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Tianjin, Wenzhou, Wuhan, Xiamen, Xi'an, Xiangyang, Yantai, Zhengzhou
- Age
- 18 years and over
- People
- 480 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06340568EU 2023-507525-42-00Registry updated 2026-10-16
Phase 2RecruitingTrial-stage medicine
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
- Where
- Tianjin
- Age
- 18 years to 70 years
- People
- 30
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT06917092Registry updated 2026-10-16
No phaseNot yet recruitingResearch participation
Effect of Weight Management on AMPK Activation in the Adjunctive Treatment of Endometrial Cancer
- Where
- Beijing
- Age
- 18 years and over
- People
- 160
- Run by
- Peking University People's Hospital
See details and how to joinNCT07879365Registry updated 2026-10-16
Phase 1/2RecruitingTrial-stage medicine
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Beijing, Changsha, Chongqing, Guangzhou, Kunming, Shandong
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482EU 2022-502759-70-01Registry updated 2026-10-13
Phase 3RecruitingTrial-stage medicine
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linhai, Linyi, Liuzhou, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Taiyuan, Wenzhou, Wuhan, Xiamen, Xi'an, Yibin, Zhanjiang, Zhengzhou
- Age
- 18 years and over
- People
- 1,123 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06952504EU 2024-519331-42-00Registry updated 2026-10-13
Phase 3RecruitingTrial-stage medicine
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Jining, Kunming, Lanzhou, Nanchang, Nanning, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Ürümqi, Wuhan, Xi'an, Xuzhou, Yibin
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06989112EU 2023-508056-19-00Registry updated 2026-10-13
Phase 1/2RecruitingTrial-stage medicine
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Where
- Beijing, Fuzhou, Guangzhou, Shandong, Shanghai
- Age
- 18 years and over
- People
- 233 worldwide
- Run by
- Ensem Therapeutics
See details and how to joinNCT06993844Registry updated 2026-10-13
No phaseRecruitingTrial-stage medicine
Stellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery
- Where
- Huai'an
- Age
- 18 years to 75 years
- People
- 100
- Run by
- Catherin Zhang
See details and how to joinNCT07860203Registry updated 2026-10-06
Phase 1/2RecruitingTrial-stage medicine
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Chengdu, Chongqing, Guangzhou, Jinan, Xi'an, Zhengzhou
- Age
- 18 years to 130 years
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168EU 2022-502576-23-00Registry updated 2026-10-05
Phase 2RecruitingTrial-stage medicine
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou
- Age
- 18 years to 130 years
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211EU 2023-509436-26-00Registry updated 2026-09-23
No phaseRecruitingResearch participation
Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer
- Where
- Beijing
- Age
- 18 years to 70 years
- People
- 20
- Run by
- Xiaorong Hou
See details and how to joinNCT07116213Registry updated 2026-09-16
No phaseRecruitingResearch participation
MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 228
- Run by
- Xiaorong Hou
See details and how to joinNCT07584161Registry updated 2026-09-16
Phase 2/3RecruitingTrial-stage medicine
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
- Where
- Shanghai
- Age
- 18 years to 45 years
- People
- 80
- Run by
- Xiaojun Chen
See details and how to joinNCT05316935Registry updated 2026-09-10
Phase 2/3RecruitingTrial-stage medicine
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
- Where
- Shanghai
- Age
- 18 years to 45 years
- People
- 29
- Run by
- Xiaojun Chen
See details and how to joinNCT06379113Registry updated 2026-09-10
All Endometrial cancer trials and the map
This page is not medical advice. Talk to your doctor before contacting a trial.